LAUSR

Gastric cancer (GC) is one of the most frequent malignancies worldwide. Long noncoding RNAs (lncRNAs) are found to be largely implicated in various cancers, including GC. However, the function of lncRNA VCAN antisense RNA 1 (VCAN‐AS1) in GC remains unclear. Herein, we observed a low level of VCAN‐AS1 in normal gastric tissues through NCBI and UCSC, and that VCAN‐AS1 upregulation in GC tissues was related to poor prognosis by TCGA. Furthermore, VCAN‐AS1 was found markedly enhanced in GC tissues and cell lines, while its upregulation was related with clinical outcomes of GC patients. Besides this, silencing VCAN‐AS1 represses cell proliferation, migration, and invasion but enhances apoptosis. More important, we discovered that VCAN‐AS1 expression was negatively correlated with wild‐type p53 levels in GC tissues and that p53 was negatively modulated by VCAN‐AS1 in GC cells. Furthermore, p53 suppression reversed the repression of VCAN‐AS1 silence on the biological processes of AGS cells. Intriguingly, we identified that both VCAN‐AS1 and TP53 can bind with eIF4A3, one of the core proteins in the exon junction complex. Also, we confirmed that VCAN‐AS1 negatively regulates TP53 expression by competitively binding with eIF4A3. Our findings disclosed that VCAN‐AS1 contributes to GC progression through interacting with eIF4A3 to downregulate TP53 expression, indicating that VCAN‐AS1 is a novel therapeutic strategy for GC treatment.